Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple-Negative Breast Cancer
Interventions: DRUG: Famitinib|DRUG: Camrelizumab|DRUG: nab-Palitaxel/Capecitabine/Eribulin Mesylate/Carboplatin
Sponsor: Fudan University